Barclays analyst Balaji Prasad assigned a Buy rating to Tarsus Pharmaceuticals (TARS – Research Report) today and set a price target of $60.00. The company’s shares closed yesterday at $47.57.

Tarsus Pharmaceuticals (TARS) announced the appointment of Katherine Goodrich, M.D., MHS, Chief Medical Officer of Humana Inc., to its Board of Directors. Published first on TheFly – the ultimate ...

Lee Towers, 82, was fatally injured in the collision outside the Jolly Tars pub in Victoria Road West on Monday, October ...

Use precise geolocation data and actively scan device characteristics for identification. This is done to store and access ...

On Friday, Tarsus Pharmaceuticals Inc (TARS) stock saw a modest uptick, ending the day at $39.41 which represents a slight increase of $0.52 or 1.34% from the prior close of $38.89. The stock opened ...

Tarsus Pharmaceuticals TARS is set to give its latest quarterly earnings report on Wednesday, 2024-11-13. Here's what investors need to know before the announcement. Analysts estimate that Tarsus ...

Tarsus Pharmaceuticals, Inc. (TARS) shares ended the last trading session 10.6% higher at $43.87. The jump came on an impressive volume with a higher-than-average number of shares changing hands ...

View Tarsus Pharmaceuticals, Inc. (TARS) current and estimated P/E ratio data provided by Seeking Alpha.

Detailed price information for Tarsus Pharmaceuticals Inc (TARS-Q) from The Globe and Mail including charting and trades.

TARS Project Management has shifted its focus to India’s pre-IPO market, aiming to tap into the country's private sector opportunities. The firm has received support from ADIB, a leading ...